Q2 25 EPS
$-0.35
MISS 1.92%
Est. $-0.34
Q2 25 Revenue
$3.2M
MISS 52.55%
Est. $6.7M
vs S&P Since Q2 25
+344.7%
BEATING MARKET
TNGX +365.0% vs S&P +20.2%
Market Reaction
Did TNGX Beat Earnings? Q2 2025 Results
Tango Therapeutics delivered a disappointing second quarter, missing on both the top and bottom lines as the absence of licensing revenue left a conspicuous gap in its financials. Revenue collapsed 84.0% year-over-year to $3.18 million, falling well … Read more Tango Therapeutics delivered a disappointing second quarter, missing on both the top and bottom lines as the absence of licensing revenue left a conspicuous gap in its financials. Revenue collapsed 84.0% year-over-year to $3.18 million, falling well short of the $6.70 million consensus estimate, a 52.55% miss driven primarily by the lack of any license revenue in the period, compared to the $12.10 million Tango recorded in Q2 2024 when it licensed a drug discovery program to Gilead. The net loss widened to $38.85 million, or $0.35 per share, missing the $0.34 consensus estimate by 1.92%. However, a significant one-time tailwind looms: Tango and Gilead mutually agreed to shorten their collaboration's research term, meaning the remaining $53.80 million in deferred revenue will be recognized in Q3 2025. Looking further ahead, a clinical data update for lead asset TNG462 is expected in the second half of 2025, with a registrational trial in pancreatic cancer targeted for 2026, as the company's $180.80 million cash runway extends into Q1 2027.
Key Takeaways
- • Decreased collaboration revenue due to lower research costs incurred under the Gilead collaboration
- • Absence of license revenue compared to $12.1 million in Q2 2024 from licensing a drug discovery program to Gilead
- • Lower R&D expenses from discontinued programs TNG908 and TNG348, partially offset by increased spend on TNG462, TNG456, and TNG961
TNGX YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
TNGX Revenue by Segment
With YoY comparisons, source: SEC Filings
“TNG462 has the potential to be a best-in-class PRMT5 inhibitor for the treatment of MTAP-del pancreatic and lung cancers, and we look forward to sharing data that support our conviction later this year.”
— Barbara Weber, Q2 2025 Earnings Press Release
TNGX Earnings Trends
TNGX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TNGX EPS Trend
Earnings per share: estimate vs actual
TNGX Revenue Trend
Quarterly revenue: estimate vs actual
TNGX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.31 | $-0.32 | -1.72% | $0 | -100.00% |
| Q4 25 BEAT FY | $-0.33 | $-0.29 | +11.83% | $0 | -100.00% |
| FY Full Year | $-0.90 | $-0.87 | +3.10% | $62.4M | -0.81% |
| Q3 25 BEAT | $-0.07 | $0.13 | +287.32% | $53.8M | +30.47% |
| Q2 25 MISS | $-0.34 | $-0.35 | -1.92% | $3.2M | -52.55% |
| Q1 25 MISS | $-0.35 | $-0.36 | -4.08% | $5.4M | -19.84% |